Vitamin C supplementation shows potential in phase 2 blood disorder trial

vitamin C blood cancer EVITA trial myelodysplastic syndrome clinical trial

Results from the phase 2 EVITA clinical trial suggest that daily oral vitamin C supplementation may benefit individuals with precancerous blood disorders or early-stage blood cancers. The study, published in the journal CANCER, involved 109 patients diagnosed with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS).

Participants received a daily dose of 1,000 mg of oral vitamin C for one year. An exploratory analysis revealed that those in the vitamin C group had significantly higher survival rates after approximately three years of follow-up compared to the placebo group. Additionally, the treatment group experienced fewer adverse events and showed changes in cytokine levels—inflammatory signaling molecules—that are associated with better clinical outcomes.

Despite these survival signals, the trial found no significant difference between the vitamin C and placebo groups regarding the growth rate of abnormal blood cells, which is a common indicator of progression toward leukemia. Researchers emphasized that these findings are exploratory and require confirmation through a larger phase 3 clinical trial before definitive medical recommendations can be made.

Entities

American Cancer Society · Kirsten Grønbæk · University of Copenhagen · Van Andel Institute

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Participants in the treatment group received a daily dose of 1,000 mg of oral vitamin C for one year. radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 3 SOURCES] There was no significant difference between the vitamin C and placebo groups regarding the growth rates of abnormal blood cells. radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 3 SOURCES] The trial included 109 patients diagnosed with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS). radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 2 SOURCES] A larger phase 3 clinical trial is necessary to confirm the exploratory findings of the EVITA trial. www.consultantlive.com · www.newswise.com
[● 3 SOURCES] The results of the phase 2 EVITA trial were published in the journal CANCER. radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 3 SOURCES] Vitamin C altered levels of cytokines, which are inflammatory signaling molecules, in ways associated with improved outcomes. radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 3 SOURCES] An exploratory analysis showed that participants taking vitamin C were significantly more likely to be alive after approximately three years of follow-up compared to the placebo group. radio580.com.ni · www.consultantlive.com · www.newswise.com
[● 3 SOURCES] The vitamin C group experienced fewer adverse events during the trial and follow-up period than the placebo group. radio580.com.ni · www.consultantlive.com · www.newswise.com

Sources

Esta popular vitamina podría tener un efecto prometedor en ciertos cánceres de la sangre [radio580.com.ni]

7 days ago

Vitamin C Shows Promise in Phase II Trial of Pre-Leukemia Blood Disorders [www.insideprecisionmedicine.com]

7 days ago

Oral Vitamin C Shows Possible Survival Signal in Precancerous Blood Disorders [www.consultantlive.com]

7 days ago

Phase 2 Trial Suggests Vitamin C May Benefit People with Pre- Cancer Blood Disorders [www.newswise.com]

8 days ago